Regulatory Prospective on Software as a Medical Device
Software is becoming increasingly important in medical devices and digital adoption more broadly. It is becoming more important as a medical device in its own right. (1) Currently the use of software in medical market is growing exponentially and many countries have already set guidelines for quality control and clinical evaluation for SaMD. Millions of users use AI based medical device for the diagnosis & Management of diseases. Regulation for the SaMD, IMDRF published guidance document in 2013, in EU they are regulated by EMA, in Australia they are regulated by TGA and in Canada they are regulated by Health Canada. Regulations of these countries and IMDRF were reviewed and articles of challenges in artificial intelligence based medical devices reviewed. There are also many challenges like cybersecurity, safety, and decommissioning, high cost of device and also the design and development process. The objective is to focus on SaMD’s regulations and Challenges.
2. IMDRF. Software as a Medical Device (SaMD): Key Definitions [Internet]. IMDRF; 2013 [cited 2022 Aug 22]. Available from:
3. Grell AS. QbD group Blog. SaMD versus MDSW: what’s the difference between Software as a Medical Device and Medical Device SoftWare? [Internet]. blog; 2021 Sep 01 [cited 2022 Aug 22]. Available from:
4. FDA. Software as a Medical Device (SaMD) [Internet]. US FDA; 2018 Apr 12 [cited 2022 Aug 21]. Available from:
5. FDA. Policy for Device Software Functions
and Mobile Medical Applications [Internet]. US FDA; 2013 Sep 25 [cited 2022 Aug 22]. Available from:
6. Rimsys. Software as a medical device (SAMD) - classification overview [Internet]. 2022 Feb 07 [cited 2022 Aug 22]. Available from:
7. IMDRF. "Software as a Medical Device": Possible Framework for Risk Categorization and Corresponding Considerations [Internet]. IMDRF; 2014 Sep 18 [cited 2022 Aug 23]. Available from:
8. Medcitynews. Top 7 challenges facing the medical device market. [Internet]. 2021 Aug 25 [cited 2022 Aug 24]. Available from:
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM